Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is projected to issue its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $2.36 per share and revenue of $804.21 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $138.98 on Wednesday. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $160.18. The firm has a market capitalization of $13.86 billion, a P/E ratio of 33.25, a P/E/G ratio of 0.64 and a beta of 0.31. The company’s fifty day moving average price is $142.97 and its 200 day moving average price is $140.38.

Insider Buying and Selling

In related news, Director Leslie V. Norwalk sold 1,190 shares of Neurocrine Biosciences stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director directly owned 6,239 shares in the company, valued at $967,606.51. This trade represents a 16.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the transaction, the insider owned 43,405 shares of the company’s stock, valued at approximately $6,929,608.25. The trade was a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,966 shares of company stock valued at $8,625,166 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently added to or reduced their stakes in the company. Fred Alger Management LLC boosted its holdings in Neurocrine Biosciences by 5.6% in the 3rd quarter. Fred Alger Management LLC now owns 2,122 shares of the company’s stock valued at $298,000 after purchasing an additional 113 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 32,956 shares of the company’s stock valued at $4,626,000 after buying an additional 239 shares during the period. Coldstream Capital Management Inc. boosted its stake in shares of Neurocrine Biosciences by 8.3% in the third quarter. Coldstream Capital Management Inc. now owns 4,090 shares of the company’s stock valued at $574,000 after buying an additional 315 shares in the last quarter. Finally, Snowden Capital Advisors LLC grew its holdings in Neurocrine Biosciences by 6.4% during the second quarter. Snowden Capital Advisors LLC now owns 5,738 shares of the company’s stock worth $721,000 after acquiring an additional 346 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several research reports. Wall Street Zen cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright raised their price target on Neurocrine Biosciences from $168.00 to $198.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. UBS Group reduced their price objective on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Piper Sandler increased their price objective on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Finally, Truist Financial cut their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $174.25.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.